Researchers have discovered that plant-derived phytochemicals and their gut microbiome metabolites control the effectiveness of PI3K inhibitors in cancer therapy. The study reveals that dietary components, especially soy compounds processed by gut bacteria, can alter drug metabolism and impact treatment outcomes.